Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EXACT SCIENCES CORPEXAS · Entity 56619 | Director | June 12, 2025 | June 16, 2025 |
| Renalytix plcRNLX · Entity 7446 | Director | November 20, 2023 | November 22, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EXACT SCIENCES CORP
Report date June 12, 2025 · Filed June 16, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,312 |
Reported balance
After 2025-06-12 transaction · row 1
1 source rowRow 1 · 2025-06-12 · Grant · Acquired 5,398 · Balance 34,312 F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy.
Renalytix plc
Report date November 20, 2023 · Filed November 22, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2033-11-19 | Direct | 95,000 |
Reported balance
After 2023-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-11-20 · Grant · Acquired 95,000 · Balance 95,000 F1: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243). F2: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243).
F2: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 12, 2025 Filed Jun 16, 2025 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,398 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-086884 · ownership.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,312 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 13, 2024 Filed Jun 17, 2024 17:30 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,444 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074411 · ownership.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,419 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 13, 2024 Filed Dec 20, 2024 16:30 UTC Amendment | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,939 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-139094 · ownership.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,914 F1 · shares: On June 17, 2024, the Reporting Person filed a Form 4 which, due to an administrative error, incorrectly reported that the Reporting person had been awarded 5,444 shares of restricted stock pursuant to the Company's non-employee director compensation policy. This amendment to Form 4 is being filed to reflect the correct amount of shares awarded pursuant to the policy. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 20:42 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 5,000 | $57.50 | $287,500.00 |
DisclosureSEC source: 0001209191-24-004241 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,975 F1 · shares: The sale reported in this field was effected pursuant to a Rule 10b5-1 trading plan entered into on November 6, 2023. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 21:28 UTC | Renalytix plc RNLX · Entity 7446 | GrantEmployee Stock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001209191-23-056477 · doc4.xml · derivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,000 Underlying: Ordinary Shares · 95,000 shares Expires 2033-11-19 F1 · derivative.exercise_price: The exercise price is 0.245 pounds sterling. The U.S. dollar equivalent of the exercise price is $0.304 using the Bank of England rate as of November 17, 2023 (1.00 pound sterling = $1.243). F2 · derivative.exercise_date: One twelfth (1/12th) of the shares subject to the option award shall vest in equal quarterly installments commencing on February 20, 2024, subject to the Reporting Person's continuous service. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 16:27 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 4,678 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036316 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,975 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 17:20 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 5,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-036402 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,297 F1 · shares: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| June 30, 2021 Filed Jul 2, 2021 16:10 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 2,675 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-044920 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,691 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 5,257 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-20-044721 · doc4.xml · derivative · entry 5 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,257 shares Expires 2021-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 4,608 | $0.00 Strike: $10.18 | $0.00 |
DisclosureSEC source: 0001209191-20-044721 · doc4.xml · derivative · entry 4 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,608 shares Expires 2022-07-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 9,865 | $94.00 | $927,310.00 |
DisclosureSEC source: 0001209191-20-044721 · doc4.xml · nonDerivative · entry 3 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,016 F2 · shares: The sales reported in this field were effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 5,257 | $8.52 | $44,789.64 |
DisclosureSEC source: 0001209191-20-044721 · doc4.xml · nonDerivative · entry 2 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,881 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 16:58 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 4,608 | $10.18 | $46,909.44 |
DisclosureSEC source: 0001209191-20-044721 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| July 23, 2020 Filed Jul 24, 2020 16:31 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 2,558 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-043601 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,016 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 15,772 | $0.00 Strike: $8.52 | $0.00 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · derivative · entry 13 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,772 shares Expires 2021-07-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 7,667 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · derivative · entry 12 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,667 shares Expires 2020-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionStock Option (right to buy) · Derivative | 19,168 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · derivative · entry 11 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,168 shares Expires 2020-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 100 | $120.24 | $12,024.00 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 10 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,458 F2 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 25, 2019, a portion of which were sold to cover certain tax liabilities arising out of the vesting of shares of restricted stock. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 8,897 | $119.63 | $1,064,348.11 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 9 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,558 F2 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 25, 2019, a portion of which were sold to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $119.23 to $120.23, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 9,626 | $118.73 | $1,142,894.98 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 8 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,455 F2 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 25, 2019, a portion of which were sold to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.20 to $119.18, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 9,572 | $117.72 | $1,126,815.84 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 7 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,081 F2 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 25, 2019, a portion of which were sold to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.18 to $118.18, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 2,300 | $116.47 | $267,881.00 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 6 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,653 F2 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 25, 2019, a portion of which were sold to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.13 to $116.96, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 9,284 | $115.65 | $1,073,694.60 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 5 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,953 F2 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 25, 2019, a portion of which were sold to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.115 to $116.10, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | SaleCommon Stock | 2,828 | $114.83 | $324,739.24 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 4 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,237 F2 · shares: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on February 25, 2019, a portion of which were sold to cover certain tax liabilities arising out of the vesting of shares of restricted stock. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.09 to $115.08, inclusive. The reporting person undertakes to provide to Exact Sciences Corporation, any security holder of Exact Sciences Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 15,772 | $8.52 | $134,377.44 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 3 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,065 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 7,667 | $3.43 | $26,297.81 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 2 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| July 31, 2019 Filed Aug 2, 2019 16:24 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | Exercise / conversionCommon Stock | 19,168 | $3.43 | $65,746.24 |
DisclosureSEC source: 0001209191-19-044253 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of common stock received upon exercise of a stock option award. Read SEC document |
| July 25, 2019 Filed Jul 26, 2019 17:00 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 2,784 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043378 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,458 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| July 26, 2018 Filed Jul 30, 2018 19:42 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 4,401 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-044483 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,998 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
| May 01, 2018 Filed Feb 8, 2019 16:55 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GiftCommon Stock | 68,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008600 · doc5.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,674 Read SEC document |
| July 27, 2017 Filed Jul 31, 2017 17:21 UTC | EXACT SCIENCES CORP EXAS · Entity 56619 | GrantCommon Stock | 7,119 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-046737 · doc4.xml · nonDerivative · entry 1 LEVANGIE DANIEL J · CIK 0001187406 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,597 F1 · security: These shares of restricted stock were issued pursuant to the Company's non-employee director compensation policy. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.